Laronde Appoints Pablo J. Cagnoni as Chief Government Officer

Thank you for reading this post, don't forget to subscribe!

SOMERVILLE, Mass., November 17, 2022–(BUSINESS WIRE)–Laronde, the corporate pioneering Countless RNA™ (eRNA) – a novel, engineered type of RNA that may be programmed to precise proteins contained in the physique for breakthrough remedies – immediately introduced Pablo J. Cagnoni, M.D. as its Chief Government Officer. Dr. Cagnoni, a Laronde board member since November 2021, succeeds John Mendlein, Flagship Pioneering Government Companion and Laronde’s Chairman, who had been serving as the corporate’s interim CEO since August. Dr. Cagnoni stepped down as President and CEO of Rubius Therapeutics and have become an Government Companion at Flagship Pioneering.

“Pablo’s deep expertise in all levels of drug growth, firm constructing, and capital formation in each non-public and public markets, alongside along with his experience in constructing platform firms make him effectively positioned to guide Laronde by means of this vital subsequent chapter,” stated John Mendlein, Chairman of Laronde and Government Companion, Flagship Pioneering. “I sit up for persevering with to work with Pablo to assist Laronde advance a brand new class of medicines that can in the end drive extraordinary well being outcomes for sufferers.”

“Laronde is an distinctive firm constructed on a really distinctive platform with the potential to vary the way in which we method drugs,” stated Pablo J. Cagnoni, MD, Chief Government Officer, Laronde and Government Companion, Flagship Pioneering. “I’m energized by Laronde’s crew and the momentum they’ve created, and sit up for main the corporate, in addition to working intently with my colleagues at Flagship, to exhibit the promise of programmable medicines by means of eRNA.”

About Pablo J. Cagnoni, M.D.

Pablo J. Cagnoni is an oncologist and pharmaceutical govt who has been dedicated to advancing the event of breakthrough remedies for folks with most cancers and different illnesses all through his profession. He has performed a key function within the growth, approval, and commercialization of greater than 20 life-changing remedies, together with Afinitor®, Kyprolis® and Tarceva®.

Dr. Cagnoni most not too long ago served as President and Chief Government Officer of Rubius Therapeutics. Earlier than becoming a member of Rubius in 2018, Dr. Cagnoni served as President and Chief Government Officer of Tizona Therapeutics, a privately held biotech firm centered on growing subsequent technology immunotherapies for the remedy of most cancers. He joined Tizona as the corporate’s first worker and grew the group to assist the submitting of its first Investigational New Drug software. In 2020, Gilead Sciences secured an unique choice to amass Tizona for as much as $1.5 billion.

Previous to Tizona, he served as President of Onyx Prescription drugs (acquired by Amgen), the place he had international strategic oversight and accountability of the enterprise from early product growth to commercialization of the Onyx portfolio. Dr. Cagnoni joined Onyx in March 2013, as Government Vice President, International Analysis and Growth and Technical Operations, and was named President in October 2013, when Onyx grew to become an Amgen subsidiary. Beforehand, he was Senior Vice President and International Head of Scientific Growth at Novartis Oncology. From 2007 to 2009, Dr. Cagnoni was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Prescription drugs) and, previous to that, Chief Medical Officer of OSI Prescription drugs (acquired by Astellas).

Earlier in his profession, he served as Assistant Professor of Medication, College of Colorado Bone Marrow Transplant Program, the place he cared for sufferers present process stem cell transplants. Dr. Cagnoni earned his medical diploma from College of Buenos Aires College of Medication, and accomplished his fellowship in Hematology and Oncology on the Mount Sinai Medical Heart, New York and a fellowship in Stem Cell Transplantation on the College of Colorado Well being Sciences Heart.

Dr. Cagnoni is Chairman of Rubius Therapeutics and a member of the Board of Administrators for Fusion Prescription drugs, Laronde, Repertoire Immune Medicines, and Synthekine. He serves on the Rising Corporations Part Governing Board of the Biotechnology Innovation Group (BIO), the Board of Trustees for the Bay Space Discovery Museum and is a member of the Council on Overseas Relations. He beforehand served as a board member for CRISPR Therapeutics, Harpoon Therapeutics, Tizona Therapeutics and Tango Therapeutics and was Government Chairman of Blade Therapeutics.

About Countless RNA™

Ribonucleic Acids, or RNAs, play a major function in biology. Amongst their features, they supply the “code” that instructs cells to provide or regulate proteins, the constructing blocks of life and vital regulators of illness processes. As a result of RNAs present coded directions to cells, they are often programmed to provide particular results. This method has been validated by the profitable growth of a number of vital RNA-based medicines, however RNA’s potential as a drug growth modality has simply begun. Countless RNA™, or eRNA, was invented at Flagship Labs and is a brand new class of artificial, closed-loop RNA. As a result of eRNA has no free ends, it’s not acknowledged by the immune system and may be very steady, enabling a protracted length of protein expression. As well as, eRNA can serve protein-coding and non-protein-coding features, and its protein translation capabilities are utterly modular — switching an eRNA “protein sequence cassette” allows the expression of a unique protein or a number of proteins that may be tuned as wanted on an application-by-application foundation.

About Laronde

Laronde is pioneering a platform that provides a totally novel approach of modulating human biology. Countless RNA™ (eRNA), invented at Flagship Labs, is a uniquely engineered RNA that may be programmed to precise various proteins contained in the physique. It’s persistent, non-immunogenic, permits for repeat dosing, and affords flexibility in formulation and supply. Laronde was based in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The corporate is quickly scaling to assist the parallel growth of a number of packages throughout many illness areas. To study extra, please go to the corporate’s web site at https://www.laronde.bio/ or Twitter and LinkedIn.

View supply model on businesswire.com: https://www.businesswire.com/information/house/20221117005337/en/

Contacts

Media:
Courtney Heath, Scient PR
[email protected]



Supply hyperlink